Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double‐blinded randomised placebo‐controlled trial
Study context
- Population
- Adults aged 25–70 years with T1D of duration ≥2 years, BMI ≥25 kg/m², HbA1c ≥7% and ≥1 cardiovascular risk factor (microalbuminuria, hypertension or anti-hypertensive treatment, hyperlipidemia or lipid lowering therapy, current smoking)planned
- Participants
- 60 adults
- Planned comparison
- Semaglutide vs placebo
- Primary endpoint
- Carotid femoral pulse wave velocity (arterial stiffness), as a surrogate marker of cardiovascular risk
Methodological detailsphase 2, double-blind, placebo-controlled
- Phase 2
- Double-blind
- Placebo-controlled
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double‐blinded randomised placebo‐controlled trial. Diabet Med. Published 9 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →